NovoCure Limited reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 127.32 million compared to USD 131 million a year ago. Net loss was USD 49.49 million compared to USD 26.58 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 0.25 a year ago. Diluted loss per share from continuing operations was USD 0.46 compared to USD 0.25 a year ago.
For the nine months, sales was USD 375.55 million compared to USD 409.41 million a year ago. Net loss was USD 159.96 million compared to USD 55.23 million a year ago. Basic loss per share from continuing operations was USD 1.51 compared to USD 0.53 a year ago. Diluted loss per share from continuing operations was USD 1.51 compared to USD 0.53 a year ago.